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The optimal management strategy for patent ductus arteriosus in preterm infants remains
a topic of debate. Available evidence for a treatment strategy might be biased by the
delayed spontaneous closure of the ductus arteriosus in preterm infants, which appears
to depend on patient characteristics. We performed a systematic review of all literature
on PDA studies to collect patient characteristics and reported numbers of patients with a
ductus arteriosus and spontaneous closure. Spontaneous closure rates showed a high
variability but were lowest in studies that only included preterm infants with gestational
ages below 28 weeks or birth weights below 1,000 g (34% on day 4; 41% on day 7)
compared to studies that also included infants with higher gestational ages or higher birth
weights (up to 55% on day 3 and 78% on day 7). The probability of spontaneous closure
of the ductus arteriosus keeps increasing until at least 1 week after birth which favors
delayed treatment of only those infants that do not show spontaneous closure. Better
prediction of the spontaneous closure of the ductus arteriosus in the individual newborn
is a key factor to find the optimal management strategy for PDA in preterm infants.
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INTRODUCTION
After preterm birth, the ductus arteriosus often remains open. Patent ductus arteriosus (PDA)
in preterm infants has been associated with prolonged ventilation, bronchopulmonary dysplasia
(BPD), and necrotizing enterocolitis potentially caused by pulmonary overcirculation and systemic
hypoperfusion (1). It is unclear if these associations reflect a causal relationship or if PDA is a
marker of poor condition and outcome, because outcomes of well-designed and controlled trials
are still awaited (2). Treatment options include fluid restriction, pharmacological intervention with
non-steroidal anti-inflammatory drugs (NSAIDs) or paracetamol, or closing the duct by surgical
ligation or heart catheterization. All of these therapeutic options have their side-effects or specific
risks in preterm infants. As a consequence, there is an ongoing worldwide discussion about the
optimal management of PDA in preterm infants (3). This discussion is complicated by the lack of
extensive knowledge on the (patho)physiology of the ductus arteriosus in preterm infants.
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Intrauterine, the ductus arteriosus is needed and remains open
due to the hypoxic fetal environment and by prostaglandins
E2 (PGE2) produced by the placenta (4). Vasodilatation is
further enhanced by nitric oxide (NO) produced by the wall
of the ductus arteriosus (5). Upon term birth, the ductus
arteriosus normally closes within hours. This is the result of
different complex physiologic mechanisms that include changes
in pulmonary and systemic vascular resistance, increase in
arterial oxygen pressure, decreasing levels of prostaglandins and
changes in different mediators and growth factors (6). After
preterm birth, however, the ductus arteriosus frequently remains
patent. Even after functional closure of the ductus arteriosus,
either spontaneous or by pharmacological treatment, it might
re-open in preterm infants afterwards caused by infection or
increased inflammation (7).
Although the high levels of prostaglandins produced by the
placenta also drop after preterm birth, the ductus arteriosus
seems to remain much more sensitive to both PGE2 and NO in
preterm infants compared to term born infants, due to increased
expression of—and binding to—prostaglandin receptors in the
ductal wall (5, 8). In addition to that, oxygenation and vascular
resistance after preterm birth are hampered by an immature
cardiovascular system and insufficient breathing whereas oxygen
targets are decreased to prevent retinopathy of prematurity (9).
A substantial part of the preterm infants with PDA still
seems to show delayed ductus closure without any intervention
(10). The advantage of a wait-and-see PDA treatment strategy
above intervention in the 1st days after birth (<72 h) may be
that only those newborns without spontaneous ductus arteriosus
closure are exposed to treatment and its potential side effects.
On the other hand, early treatment strategy may be favored
because the pharmacological closure rate seems to be highest
on the 1st days of life (11, 12). Despite the limited studies
on delayed treatment with NSAIDs and paracetamol, this late
treatment seems less effective (13, 14). NSAIDs and paracetamol
may enhance the spontaneous closure process. Therefore, the
discussion on management of PDA in preterm infants cannot
neglect the spontaneous closure, although a clear overview of the
spontaneous closure rates is yet lacking. In this study, we aimed to
provide such an overview of all available data from PDA studies
to investigate and analyze the rates of spontaneous closure of
the PDA.
METHODS
To retrieve all relevant evidence on the physiological
spontaneous ductus arteriosus closure in preterm infants,
we performed a thorough literature search. All studies
published after 1990 that met both of the following criteria
were considered eligible: (1) trials of any form including
randomized controlled trials (RCTs), controlled clinical trials,
quasi experimental studies [(un)controlled before and after
studies], prospective and retrospective cohort studies and
case-control studies and (2) trials with a clearly described timing
of echocardiography to identify the presence or absence of a
ductus arteriosus. Case series and case reports were excluded,
as well as studies that reported on spontaneous closure after
discharge. To examine spontaneous closure of the PDA, data
on spontaneous closure before any intervention were collected
and analyzed.
Search Strategy
A literature search was performed in collaboration with an
experienced librarian. The search was done in MEDLINE,
EMBASE, Cochrane central, Web of science, and Google Scholar
until 2018 and included only English written articles. The
following search terms were used “patent ductus arteriosus,”
“PDA,” “preterm,” “VLBW,” and/or “prematurity.” A more
detailed search strategy for each library is available in
Supplementary File 1.
The retrieved titles, abstracts, and full text were screened
by two independent reviewers (JdK and FvB) to assess
their eligibility according to pre-established criteria. Duplicate
publications were excluded. The data extraction was done by the
same two independent reviewers (JdK and FvB). Discrepancies
were either resolved by discussion or by consulting a third
reviewer (SS).
Data Synthesis
We developed a data extraction sheet, pilot-tested it on 10
randomly-selected included studies, and refined it accordingly.
One review author (JdK) extracted the following data from
included studies and the second author (FvB) checked the
extracted data. Disagreements were resolved by discussion
between the two review authors; if no agreement could be
reached, it was planned a third author (SS) would decide. The
data that was used included the following: total number of
included neonates, their gestational age and birth weight, timing
of the echocardiographic evaluation, and the number of neonates
with closed ductus arteriosus at those times. Because only
baseline reports of the occurrence of PDA were included, before
any intervention for PDA was initiated, no bias of individual
studies was expected.
Articles were categorized based on the inclusion criteria that
were used in the studies for gestational age (GA) and birth
weight (BW). Based on frequently used inclusion cut-off values
of GA and BW, four different groups were defined prior to data
collection: group 1: GA < 28 weeks and/or BW < 1,000 g, group
2: GA < 30 weeks and/or BW < 1,250 g, group 3: GA < 32 weeks
and/or BW < 1,500 g, and group 4: GA < 37 weeks and/or BW
< 2,500 g. If only GA or BWwas given as inclusion criterion, this
determined the category of the article, if both GA and BW were
given as inclusion criteria, GA was leading for categorization.
Studies were only included in one group: those included in group
1 were not included in groups 2–4, studies in group 2 were not
included in group 3 and 4, and studies in group 3 were not
included in group 4.
Data Analysis
The primary outcome of this systematic review was the rate of
spontaneous closure of the ductus arteriosus in preterm infants
as evaluated by echocardiography. A closed ductus arteriosus is
defined as a ductus arteriosus that shows complete closure or
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no doppler flow on echocardiography as reported in the original
reports. The closure rate was calculated as the part of patients
with a closed ductus within a certain cohort (number of patients
with a closed ductus divided by the total number of patients) at
a time-point. To further explore how the observed trends were
correlated to the maturational status of the patient, different
subgroup analyses were performed for the different GA and
BW groups.
R Software (V 3.5.1) was used in R Studio (V 1.1.643) to group,
summarize, and visualize the data. The percentage of patients
with PDA was plotted against postnatal age. To differentiate
spontaneous closure between the different GA and BW groups,
a linear smoothed line weighted by the total number of patients
of each study was drawn. Mean percentages of patients with
PDA of studies that performed an echocardiography on postnatal
day 3 (between 72 and 95.9 h) and day 7 (between 168 and
191.9 h) were calculated, and were weighted by the number of
patients in each study. These time-points were included because
the ductus is mostly evaluated during the 1st days of life (<72 h)
and administered courses of pharmacotherapy normally take 3 or
6 days.
RESULTS
Our literature search resulted in a retrieval of 8,173 records. After
removing the duplicates 3,607 remained. Reading of the titles
and abstracts resulted in 332 eligible articles. The arguments for
exclusion of 233 articles after full text screening are listed in
Supplementary File 2. The clinical characteristics of the included
studies are summarized in Supplementary File 3. All studies
were published between 1990 and 2018. Ninety-nine articles
with a total of 29,532 patients were included in the analysis. In
Figure 1, a flow diagram is presented of the studies retrieved
for this review. Figure 2 presents the reported percentages of
patients with a PDA for each individual study with increasing
postnatal ages. On PNA day 3 (all reported outcomes observed
between 72 and 96 h of life), the mean reported percentage
of patients that experienced spontaneous closure of the ductus
arteriosus weighted by the number of patients was 47% (range
9–96%). On PNA day 7 (168–192 h) this percentage increased to
61% (11–100%).
Subgroup Analysis
InTable 1, the reported characteristics of all studies are presented
per group, as well as the percentages of PDA closure at postnatal
age days 3 and 7 and the studies and number of patients these are
based on.
Eleven different articles were included in group 1 which
contained preterm infants with a gestational age under 28 weeks
and/or birth weight under 1,000 g (15–20, 54, 63–66). The
median of reportedmean ormedian GAs of the 17,156 patients in
group 1 was 26.0 (range of mean/median 25.5–26.6) weeks. The
median birth weight was 832 (range of medians 802–851) g. Exact
numbers for gestational ages and birth weights were not available
for three studies (19, 63, 66). Two of the 11 studies performed
multiple cardiac ultrasounds to evaluate the PDA, ranging from
24 h until 61 days of postnatal age (15, 18). Seven of the 11 studies
performed their first ultrasound at day 3 after birth.
Twenty articles were included in group 2 (GA < 30 weeks
and/or BW < 1,250 g) (11, 21–29, 67–76). The median of the
reported mean or median GA of the 2,980 patients in group 2
was 28.0 (range 26.2–28.8). The median of the reported mean
or median birth weight was 1,028 (range 797–1,259) g. The
exact gestational ages and birth weights were not available for
four studies (28, 29, 69, 74). Seven of the 20 studies performed
multiple cardiac ultrasounds to evaluate the PDA (21, 24, 25, 27,
67, 72, 73). The echocardiography was performed between 5 h
and 28 days of postnatal age in all studies.
Forty-nine studies that included a total of 6,946 patients were
eligible for group 3 (GA < 32 weeks and/or BW < 1,500 g) (30–
45, 55–59, 77–103, 132). The median GA was 28.6 (range 26–31)
weeks. The median birth weight was 1,120 (range 794–1,595) g.
Exact gestational ages and birth weights were not available for
nine studies (35, 38, 41, 42, 44, 85, 96, 100, 104). Multiple cardiac
ultrasounds where performed in 14 of the 49 studies and were
performed between 6 and 338 h of postnatal age.
Nineteen studies used GA < 37 weeks and/or birthweight <
2,500 g as inclusion criteria (group 4), in which a total of 2,450
patients were included (46–53, 60–62, 105–112). The median
gestational age was 30.9 (range 28.1–31.2) weeks. The median
birth weight was 1,479 (range 950–1,917) g. Gestational ages
and/or birth weights were not available for six studies (47, 50, 53,
105, 107, 109). Six of the 19 studies performed multiple cardiac
ultrasounds at varying post-natal ages between 24 and 168 h.
In Figures 3 and 4 the reported percentage of preterm infants
with PDA are presented for each subgroupwith a postnatal age up
to 3 and 7 days, respectively. To account for the large differences
in number of patients (range 18–15,971), the size of the dots is
scaled by the square root of the number of patients. At postnatal
age day 3 (72–95.9 h), mean percentage of PDA closure was 34%
for group 1, weighted by the number of patients in each study
(range 9–71%). In group 2, this percentage was 47% (33–98%),
and in group 3 this was 48% (22–65%). In group 4, the weighted
mean was 55% at PNA 3 (15–97%).
At PNA 7, the weighted average of patients with a closed
PDA was 41% for group 1 (11–97%). Of group 2, only one
study was available with a reported percentage of closure at
PNA 7, which was 77% (20 of 26 patients) (24). In group
3, the weighted average closure was 63% (38–100%) at PNA
day 7, and for group 4 this was 78% (67–97%). Comparing
Figures 2–4 clearly show that with increasing postnatal ages the
spontaneous closure continuous and PDA rates decrease. This is
most obvious in the studies that also included the oldest groups
of infants.
DISCUSSION
In this review, spontaneous closure rates of the ductus arteriosus
in preterm neonates were systematically evaluated in 99 studies
that represented 29,532 patients. As expected, we observed
increasing rates of ductus closure with post-natal age and
higher spontaneous closure rates in studies that also included
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FIGURE 1 | Flow diagram of the studies retrieved for this review.
patients with higher gestational ages. Spontaneous closure,
however, occurs not only in the 1st day of life, but continues
throughout the 1st week of life. Our systematic review revealed
34% spontaneous closure on the 3rd day of life (72–96 h) in the
studies that only included the youngest group of infants (<28
weeks of GA and/or birthweight <1,000 g). If older infants were
also included in studies, these closure rates increased up to 55%.
At PNA day 7 (168–192 h) the ductus arteriosus was closed in
41% of the newborns in studies of the youngest infants and up
to 78% in the studies that also included older gestational age
groups. Because of a lack of detailed reports in the individual
studies on subgroups of patients and the lack of longitudinal
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FIGURE 2 | Reported percentages of closure of patent ductus arteriosus of all included studies, up to a postnatal age of 28 days. Each dot represents a reported
percentage, whose size represents the square root of the total number of patients of that observation.
assessment of the ductus arteriosus we were unable to provide a
mathematical function of spontaneous ductus closure in preterm
infants. Such a function that could predict spontaneous closure
in an individual patient would be an ultimate goal to guide
PDA management in individual patients. High quality datasets
with repeated echocardiographic assessments of neonatal
patients treated in current neonatal intensive care units are
needed first.
Studies that reported on PDA showed large heterogeneity, not
only in included patient populations, but also in the definition
of a hemodynamically significant PDA (hsPDA) (113). It is quite
clear that the significance of a PDA is not only determined by
the diameter of the ductus, as was used in the current review, but
also by the pulmonary vascular resistance. The lack of consensus
on the definition of a hsPDA is partly based on the lack of
validated echocardiographic markers and cutoff values. van Laere
et al. (114) proposed to standardize essential echocardiographic
measurements for the assessment of hemodynamic significance
of a PDA. These consist of evaluation of the ductus arteriosus
itself (including the diameter, flow direction, and velocity),
indices of pulmonary overcirculation (La:Ao, left pulmonary
artery diastolic flow) and indices of systemic shunt effect (flow
pattern in aorta descendens, tructus coeliacus, or middle cerebral
artery) (114). The LA:Ao ratio, ductal diameter and diastolic
flow in the left pulmonary artery are easy to measure and seem
the most accurate and easy to determine markers for a hsPDA
(115). In our aim to select those infants that would not show
spontaneous closure and might actually need PDA treatment
these markers would be useful.
Currently, there is no international consensus on PDA
management. It is unclear if, how and when PDA in
preterm infants should be treated. More specifically, it is
unclear if PDA needs treatment because it is unknown
which preterm infants might benefit more from treatment
than others. Therefore, prophylaxis, early treatment (<24 h),
late treatment (72 h), symptomatic treatment and wait and
see strategies are currently used alongside each other (116).
Better knowledge on the spontaneous closure and physiology
of the ductus arteriosus in preterm infants may help to
determine the optimal management strategy. This is even more
important as prophylactic as well as therapeutic treatment
strategies are associated with risks for adverse effects, such
as intraventricular hemorrhages and decreased renal function
that might have severe consequences in these vulnerable
patients. Treatment of the PDA, pharmacologically or surgically,
should therefore be reserved for those patients who may
benefit from it.
Next to the ongoing discussion on the type of drug
being either ibuprofen, indomethacin, or acetaminophen (117–
124), the timing of treatment initiation varies widely between
studies, and might explain reported differences in efficacy.
As spontaneous ductus closure increases with PNA, part of
ductus closure reported in prophylactic and early treatment
studies may be due to spontaneous closure rather than drug
treatment. Efficacy of PDA pharmacotherapy seems to decrease,
with post-natal age, even if dosages are increased with PNA
to correct for increased clearance with age (10, 13). This
suggests either a certain window of opportunity for PDA
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TABLE 1 | Summary of reported mean or median gestational age and birthweight of the included studies, and reported percentages of PDA closure at postnatal age
days 3 and 7.
Group 1 Group 2 Group 3 Group 4 All studies
Inclusion criteria GA < 28 weeks
and/or birth weight
<1,000 g
GA < 30 weeks and/or
birth weight <1,250 g
GA < 32 weeks and/or
birth weight <1,500 g
GA < 37 weeks and/or
birth weight <2,500 g
Number of studies 11 20 49 19 99
Total number of
patients






28.0 [26.2–28.8] (13) 28.4 [26.0–30.0] (22) 30.8 [30.2–31.1] (7) 28.1 [25.5–31.2] (50)
Median [median
(range)]
– 28.0 [–] (2) 29 [27–31] (15) 31.0 [28.1–31.0] (5) 29.0 [27.0–31.0] (22)
Not reported (n) 3 5 12 7 27
Birth weight
Mean [median (range)] 818 [802–851] (8) 1,028 [(797–1,259] (13) 112 [794–1,371] (22) 1,543 [1,355–1,917] (7) 1,082 [794–1,917] (50)
Median [median
(range)]
– 1,060–1,062 (2) 1,160 [980–1,595] (15) 1,475 [950–1,640] (5) 1,160 [950–1,640] (22)
Not reported (n) 3 5 12 7 27
Postnatal age of cardiac ultrasound
Median postnatal age
in h (range)
72 (18–1,464) 72 (5–672) 79 (6–3,864) 72 (24–1,632 72 (5–3,864)




34% (9–71) 47% (33–98) 48% (22–65) 55% (15–79) 47% (9–96)
Number of studies with
reported percentage
6 9 16 8 39
Total number of
patients
646 978 1,709 621 3,954
Study references (15–20) (21–29) (30–45) (46–53) (15–53)




41% (11–97) 77 % (–) 63% (38–100) 78% (67–97) 61% (11–100)
Number of studies with
reported percentage
2 1 8 5 16
Total number of
patients
228 26 550 181 985
Study references (18, 54) (24) (30, 33, 43, 55–59) (46, 50, 60–62) (18, 24, 30, 33, 43, 46, 50, 54–62)
Separated by groups based on inclusion criteria.
treatment during the physiological process that is involved in
the spontaneous closure of the ductus arteriosus or the need
for higher drug exposures at older ages. Such a window can
only be identified if the rate of spontaneous closure is well-
characterized, and efficacy studies can correct for the chance of
spontaneous closure.
With the current review, we have summarized the evidence
that spontaneous closure is less likely to occur in preterm
neonates with the lowest gestational ages. Nevertheless, in
another significant number of preterm infants the ductus
arteriosus although delayed, closes spontaneously within the first
150 h of life. The presented review was limited by the lack of
detailed reports of PDA for different gestational age groups in the
included studies.While the literature was systematically reviewed
we were unfortunately unable to provide statistical analysis due
to complexity of outcome data. This also resulted in overlap of
patients in the different groups. All studies only had an upper
limit of gestational age and/or bodyweight without a lower limit
for gestational age/weight. As a consequence, the gestational
age/weight range of inclusion criteria of the included studies
increases from group 1 to 4. Therefore, the actual difference
in the occurrence of spontaneous closure between different
GA groups is bigger than observed in the present study. As
other widely used measures for ductus closure, such as LA:Ao
Frontiers in Pediatrics | www.frontiersin.org 6 September 2020 | Volume 8 | Article 541
de Klerk et al. Spontaneous PDA Closure
FIGURE 3 | Reported percentages of patients with patent ductus arteriosus up to a postnatal age of 4 days, grouped by mean or median gestational age or
birthweight if gestational age was unreported. Each dot represents one observation at the reported postnatal age. The size of the dots represents square root of the
number of patients of each observation. Lines represent a linear smooth weighted by the number of patients of each observation.
ratio were mostly missing, we defined a closed ductus as a
ductus that was visually closed or when there was no doppler
flow visible on echocardiography. As discussed previously, a
better definition of a hsPDA might be desirable and might
lead to a more precise estimation of incidence- and closure-
rates. In this study, we presented the relationships between
spontaneous closure rate and PNA as linear relationships. In
reality, the spontaneous closure rate is probably highest on
the 1st day and decreases with an asymptotic shape since in
some patients the spontaneous closure will not occur, or the
percentage of patients with PDA might even go up if the
ductus arteriosus reopens. With the available data, it is not
possible to determine whether the reported numbers of PDA
at high postnatal ages (Figure 2) are due to non-closure or
re-opening because seventy of the 99 articles performed only
one echocardiography. Therefore, there were insufficient data to
study potential reopening of the ductus arteriosus in this review.
The patency of the ductus arteriosus is regulated by the balance of
vasodilating (prostaglandin E2, nitric oxide) and vasoconstrictor
(oxygen) factors (6). Preterm neonates are more sensitive to the
vasodilating factors compared to the term neonates (5). There
is some evidence suggesting that genetic variations may play a
role in the occurrence of PDA in preterm infants. In a large
cohort of 1,013 preterm neonates Dagle et al. (125) found that
several single nucleotide polymorphisms that were associated
with PDA. For future meta-analyses, it might thus be of interest
to include genetic variations to determine their influence on
spontaneous closure.
Our systematic review was based on the assumption that
gestational age is a more important factor compared to
birthweight for patent ductus arteriosus in preterm infants.
Villamor-Martinez et al. (126) showed that small for gestational
age (SGA) infants showed a significantly reduced risk of PDA,
but their review was complicated by the heterogeneity of studies.
As SGA infants also show a much higher clearance of ibuprofen
compared to appropriate weight for age newborns these patients
form a special population that need additional attention in future
PDA studies (127).
A next step could be to find markers to repeatedly monitor
closure and pathophysiology of the ductus arteriosus. These
could include the continuously available perfusion index to
identify a hemodynamic significant PDA (51, 128) or urinary
prostaglandine levels (129). Neutrophil gelatinase-associated
lipocalin and heart-type fatty acid-binding protein are two
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FIGURE 4 | Reported percentages of patients with patent ductus arteriosus up to a postnatal age of 8 days, grouped by mean or median gestational age or
birthweight if gestational age was unreported. Each dot represents one observation at the reported postnatal age. The size of the dots represents square root of the
number of patients of each observation. Lines represent a linear smooth weighted by the number of patients of each observation.
peptides that can be measured in urine and also appear to be
promising future markers to quantify the effect of a PDA on
systemic perfusion, which makes the ductus arteriosus more
hemodynamic significant (130, 131). Relevant risk factors could
help to predict those patients whose ductus arteriosus will
remain open and for whom pharmacological treatment might
be needed.
Spontaneous closure rates increase with both gestational age
and postnatal age. This review showed that in 34% of the most
premature infants (GA < 28 weeks and/or BW < 1,000 g), the
ductus arteriosus had spontaneously closed on the 3rd day of
life (72–96 h). This increased to 41% at PNA day 7. As patients
with a GA < 28 weeks have the lowest chance of spontaneous
closure of the ductus arteriosus in the 1st days of life, studies
on PDA management should therefore focus on these most
premature patients.
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